InVivo Therapeutics Holdings PE Ratio 2010-2023 | NVIVQ
Current and historical p/e ratio for InVivo Therapeutics Holdings (NVIVQ) from 2010 to 2023. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. InVivo Therapeutics Holdings PE ratio as of June 27, 2025 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| InVivo Therapeutics Holdings PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2024-07-19 | 0.37 | 0.00 | |
| 2023-09-30 | 1.12 | $-0.87 | 0.00 |
| 2023-06-30 | 1.35 | $-1.98 | 0.00 |
| 2023-03-31 | 1.06 | $-3.95 | 0.00 |
| 2022-12-31 | 2.35 | $-5.89 | 0.00 |
| 2022-09-30 | 4.29 | $-8.14 | 0.00 |
| 2022-06-30 | 4.05 | $-7.91 | 0.00 |
| 2022-03-31 | 8.75 | $-7.69 | 0.00 |
| 2021-12-31 | 11.50 | $-7.75 | 0.00 |
| 2021-09-30 | 17.50 | $-5.50 | 0.00 |
| 2021-06-30 | 18.50 | $-15.50 | 0.00 |
| 2021-03-31 | 24.75 | $-26.00 | 0.00 |
| 2020-12-31 | 20.25 | $-85.75 | 0.00 |
| 2020-09-30 | 35.50 | $-85.75 | 0.00 |
| 2020-06-30 | 39.50 | $-291.72 | 0.00 |
| 2020-03-31 | 42.25 | $-534.72 | 0.00 |
| 2019-12-31 | 165.00 | $-683.18 | 0.00 |
| 2019-09-30 | 375.00 | $-683.18 | 0.00 |
| 2019-06-30 | 555.00 | $-780.78 | 0.00 |
| 2019-03-31 | 1162.50 | $-6,141.14 | 0.00 |
| 2018-12-31 | 1132.50 | $-8,438.44 | 0.00 |
| 2018-09-30 | 1515.00 | $-10,878.38 | 0.00 |
| 2018-06-30 | 1275.00 | $-15,818.32 | 0.00 |
| 2018-03-31 | 10125.00 | $-13,956.46 | 0.00 |
| 2017-12-31 | 14437.50 | $-15,202.70 | 0.00 |
| 2017-09-30 | 27187.50 | $-15,953.45 | 0.00 |
| 2017-06-30 | 50625.00 | $-14,264.27 | 0.00 |
| 2017-03-31 | 75937.50 | $-13,513.51 | 0.00 |
| 2016-12-31 | 78750.00 | $-14,264.26 | 0.00 |
| 2016-09-30 | 127500.00 | $-14,264.26 | 0.00 |
| 2016-06-30 | 108375.00 | $-12,387.39 | 0.00 |
| 2016-03-31 | 130875.00 | $-16,704.20 | 0.00 |
| 2015-12-31 | 135000.00 | $-24,211.71 | 0.00 |
| 2015-09-30 | 161625.00 | $-27,777.78 | 0.00 |
| 2015-06-30 | 302812.00 | $-26,839.34 | 0.00 |
| 2015-03-31 | 222750.00 | $-22,522.52 | 0.00 |
| 2014-12-31 | 99000.00 | $-15,765.77 | 0.00 |
| 2014-09-30 | 42000.00 | $-14,264.26 | 0.00 |
| 2014-06-30 | 78000.00 | $-18,768.77 | 0.00 |
| 2014-03-31 | 132000.00 | $-30,780.78 | 0.00 |
| 2013-12-31 | 172500.00 | $-40,540.53 | 0.00 |
| 2013-09-30 | 107250.00 | $-45,045.04 | 0.00 |
| 2013-06-30 | 309750.00 | $-31,531.52 | 0.00 |
| 2013-03-31 | 179250.00 | $-14,264.26 | 0.00 |
| 2012-12-31 | 130500.00 | $4,504.50 | 28.97 |
| 2012-09-30 | 116250.00 | $-36,786.79 | 0.00 |
| 2012-06-30 | 171750.00 | $-40,540.54 | 0.00 |
| 2012-03-31 | 186000.00 | $-45,045.04 | 0.00 |
| 2011-12-31 | 206250.00 | $-48,798.80 | 0.00 |
| 2011-09-30 | 49500.00 | $2,252.25 | 21.98 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.000B | $0.000B |
| InVivo Therapeutics Holdings Corp. operates as a medical device company focused on utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed as a result of traumatic spinal cord injury. The company intends to offer three products, including a biocompatible polymer scaffolding device to treat acute wound SCI; a biocompatible hydrogel for local controlled release of methylprednisolone to treat acute SCI; and a biocompatible polymer scaffolding device seeded with autologous hNSCs to treat acute and chronic SCI. InVivo Therapeutics Holdings Corp. is based in Cambridge, Massachusetts. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $233.799B | 28.11 |
| Boston Scientific (BSX) | United States | $157.605B | 39.46 |
| Stryker (SYK) | United States | $150.214B | 31.41 |
| EssilorLuxottica (ESLOY) | France | $126.765B | 0.00 |
| Medtronic (MDT) | Ireland | $110.324B | 15.64 |
| Lonza Group Ag (LZAGY) | Switzerland | $50.804B | 0.00 |
| Haleon (HLN) | United Kingdom | $46.676B | 26.62 |
| ResMed (RMD) | United States | $37.413B | 28.10 |
| GE HealthCare Technologies (GEHC) | United States | $34.057B | 16.17 |
| Agilent Technologies (A) | United States | $33.852B | 22.07 |
| Terumo (TRUMY) | Japan | $27.835B | 36.15 |
| Koninklijke Philips (PHG) | Netherlands | $23.245B | 16.31 |
| Insulet (PODD) | United States | $22.033B | 86.49 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.095B | 11.62 |
| Baxter (BAX) | United States | $15.595B | 11.64 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $13.236B | 0.00 |
| Demant (WILYY) | Denmark | $9.110B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $8.561B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $6.639B | 23.10 |
| Lantheus Holdings (LNTH) | United States | $5.638B | 14.22 |
| Prestige Consumer Healthcare (PBH) | United States | $3.998B | 17.86 |
| Perrigo (PRGO) | Ireland | $3.649B | 9.25 |
| Haemonetics (HAE) | United States | $3.545B | 16.15 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Envista Holdings (NVST) | United States | $3.334B | 27.70 |
| ICU Medical (ICUI) | United States | $3.244B | 23.92 |
| QuidelOrtho (QDEL) | United States | $1.952B | 13.43 |
| LeMaitre Vascular (LMAT) | United States | $1.866B | 41.70 |
| AtriCure (ATRC) | United States | $1.598B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.289B | 13.08 |
| Acuren (TIC) | United States | $1.271B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.111B | 25.00 |
| Phibro Animal Health (PAHC) | United States | $1.040B | 13.30 |
| Neogen (NEOG) | United States | $1.027B | 13.14 |
| BioLife Solutions (BLFS) | United States | $1.021B | 0.00 |
| Kestra Medical Technologies (KMTS) | United States | $0.907B | 0.00 |
| InMode (INMD) | Israel | $0.897B | 9.04 |
| Owens & Minor (OMI) | United States | $0.685B | 5.69 |
| CeriBell (CBLL) | United States | $0.683B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.629B | 0.00 |
| Evolus (EOLS) | United States | $0.589B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.531B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.509B | 0.00 |
| Valneva SE (VALN) | France | $0.494B | 0.00 |
| Surmodics (SRDX) | United States | $0.412B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.403B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.354B | 13.00 |
| Quanterix (QTRX) | United States | $0.332B | 0.00 |
| SNDL (SNDL) | Canada | $0.323B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.301B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.274B | 23.07 |
| Cerus (CERS) | United States | $0.271B | 0.00 |
| ZimVie (ZIMV) | United States | $0.258B | 11.72 |
| Sanuwave Health (SNWV) | United States | $0.256B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.253B | 0.00 |
| Brainsway (BWAY) | Israel | $0.250B | 66.10 |
| Cresco Labs (CRLBF) | United States | $0.246B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.233B | 69.17 |
| Biote (BTMD) | United States | $0.230B | 6.46 |
| OraSure Technologies (OSUR) | United States | $0.225B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.224B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.201B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.188B | 15.29 |
| Omeros (OMER) | United States | $0.188B | 0.00 |
| High Tide (HITI) | Canada | $0.184B | 0.00 |
| Organigram Global (OGI) | Canada | $0.181B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.177B | 0.00 |
| Exagen (XGN) | United States | $0.149B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.144B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.120B | 14.81 |
| Jin Medical (ZJYL) | China | $0.102B | 0.00 |
| Fonar (FONR) | United States | $0.092B | 11.90 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.088B | 0.00 |
| Veru (VERU) | United States | $0.085B | 0.00 |
| Apyx Medical (APYX) | United States | $0.082B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.078B | 0.00 |
| Zynex (ZYXI) | United States | $0.077B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.077B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.077B | 0.00 |
| MacroGenics (MGNX) | United States | $0.075B | 0.00 |
| InterCure (INCR) | Israel | $0.068B | 0.00 |
| Agape ATP (ATPC) | $0.066B | 0.00 | |
| ImmuCell (ICCC) | United States | $0.061B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.057B | 0.00 |
| Nephros (NEPH) | United States | $0.041B | 55.14 |
| United-Guardian (UG) | United States | $0.037B | 12.94 |
| Modular Medical (MODD) | United States | $0.037B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.027B | 0.00 |
| Safety Shot (SHOT) | United States | $0.023B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.018B | 0.00 |
| INLIF (INLF) | $0.016B | 0.00 | |
| Meihua Medical Technologies (MHUA) | China | $0.014B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.014B | 0.00 |
| Flora Growth (FLGC) | United States | $0.014B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.012B | 0.00 |
| Senestech (SNES) | United States | $0.010B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.006B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.006B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| Sharps Technology (STSS) | United States | $0.000B | 0.00 |